| Why 90% of clinical drug development fails and how to improve it? D Sun, W Gao, H Hu, S Zhou Acta Pharmaceutica Sinica B 12 (7), 3049-3062, 2022 | 541 | 2022 |
| Novel thermo-sensitive hydrogel system with paclitaxel nanocrystals: High drug-loading, sustained drug release and extended local retention guaranteeing better efficacy and … Z Lin, W Gao, H Hu, K Ma, B He, W Dai, X Wang, J Wang, X Zhang, ... Journal of Controlled Release 174, 161-170, 2014 | 206 | 2014 |
| Mitigating SOX2-potentiated immune escape of head and neck squamous cell carcinoma with a STING-inducing nanosatellite vaccine YS Tan, K Sansanaphongpricha, Y Xie, CR Donnelly, X Luo, BR Heath, ... Clinical Cancer Research 24 (17), 4242-4255, 2018 | 130 | 2018 |
| Effects of PEGylated paclitaxel nanocrystals on breast cancer and its lung metastasis H Zhang, H Hu, H Zhang, W Dai, X Wang, X Wang, Q Zhang Nanoscale 7 (24), 10790-10800, 2015 | 83 | 2015 |
| A novel localized co-delivery system with lapatinib microparticles and paclitaxel nanoparticles in a peritumorally injectable in situ hydrogel H Hu, Z Lin, B He, W Dai, X Wang, J Wang, X Zhang, H Zhang, Q Zhang Journal of Controlled Release 220, 189-200, 2015 | 74 | 2015 |
| Tumor-derived exosomes: Nanovesicles made by cancer cells to promote cancer metastasis H Chen, V Chengalvala, H Hu, D Sun Acta Pharmaceutica Sinica B 11 (8), 2136-2149, 2021 | 45 | 2021 |
| Albumin nanoparticle containing a PI3Kγ inhibitor and paclitaxel in combination with α-PD1 induces tumor remission of breast cancer in mice Y Song, L Bugada, R Li, H Hu, L Zhang, C Li, H Yuan, KK Rajanayake, ... Science translational medicine 14 (643), eabl3649, 2022 | 43 | 2022 |
| Reappraisal of anticancer nanomedicine design criteria in three types of preclinical cancer models for better clinical translation X Luan, H Yuan, Y Song, H Hu, B Wen, M He, H Zhang, Y Li, F Li, P Shu, ... Biomaterials 275, 120910, 2021 | 43 | 2021 |
| Transmembrane pathways and mechanisms of rod-like paclitaxel nanocrystals through MDCK polarized monolayer F Deng, H Zhang, X Wang, Y Zhang, H Hu, S Song, W Dai, B He, Y Zheng, ... ACS Applied Materials & Interfaces 9 (7), 5803-5816, 2017 | 37 | 2017 |
| Smart nanoparticles undergo phase transition for enhanced cellular uptake and subsequent intracellular drug release in a tumor microenvironment G Ye, Y Jiang, X Yang, H Hu, B Wang, L Sun, VC Yang, D Sun, W Gao ACS applied materials & interfaces 10 (1), 278-289, 2018 | 30 | 2018 |
| A comparative investigation between paclitaxel nanoparticle-and nanocrystal-loaded thermosensitive PECT hydrogels for peri-tumoural administration Z Lin, S Xu, W Gao, H Hu, M Chen, Y Wang, B He, W Dai, H Zhang, ... Nanoscale 8 (44), 18782-18791, 2016 | 27 | 2016 |
| Self-assembled Au@ Fe core/satellite magnetic nanoparticles for versatile biomolecule functionalization H Chen, H Hu, C Tao, RM Clauson, I Moncion, X Luan, S Hwang, ... ACS applied materials & interfaces 11 (27), 23858-23869, 2019 | 15 | 2019 |
| Optimization of the prodrug moiety of Remdesivir to improve lung exposure/selectivity and enhance anti-SARS-CoV-2 activity H Hu, MD Mady Traore, R Li, H Yuan, M He, B Wen, W Gao, CB Jonsson, ... Journal of Medicinal Chemistry 65 (18), 12044-12054, 2022 | 10 | 2022 |
| cRGDfK-grafted small-size quercetin micelles for enhancing therapy efficacy of active ingredient from the chinese medicinal herb P Xu, H Wang, H Hu, Y Ye, Y Dong, S Li, D Mei, Z Guo, D Wang, Y Sun, ... International Journal of Nanomedicine, 9173-9184, 2019 | 8 | 2019 |
| Structure‒tissue exposure/selectivity relationship (STR) correlates with clinical efficacy/safety W Gao, H Hu, L Dai, M He, H Yuan, H Zhang, J Liao, B Wen, Y Li, ... Acta Pharmaceutica Sinica B 12 (5), 2462-2478, 2022 | 7 | 2022 |
| BMS-986393 (CC-95266), a G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D)-Targeted Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Multiple … S Bal, M Htut, O Nadeem, LD Anderson Jr, H Koçoğlu, T Gregory, ... Blood 142, 219, 2023 | 5 | 2023 |
| Mechanism and clinical progress of molecular targeted cancer therapy HX Hu, XQ Wang, H Zhang, Q Zhang Yao xue xue bao= Acta Pharmaceutica Sinica 50 (10), 1232-1239, 2015 | 5 | 2015 |
| Resolving STING-mediated tumor immune microenvironment shift at single-cell resolution YS Tan, BR Heath, BD Hill, X Luo, SM Rizvi, T Moghbeli, H Hu, E Siismets, ... CLINICAL CANCER RESEARCH 26 (12), 33-34, 2020 | 2 | 2020 |
| Integrating Full Bayesian Inference and Student's t‐Distribution Method for Enhanced Outlier Handling in Caffeine Population Pharmacokinetics: Assessing Drug–Drug Interactions … Y Cheng, S Du, H Hu, X Wang, L Carayannopoulos, Y Li The Journal of Clinical Pharmacology, 2024 | 1 | 2024 |
| S193: BMS-986393 (CC-95266), AG protein–coupled receptor class C group 5 member D (GPRC5D)–targeted CAR T-cell therapy for relapsed/refractory multiple myeloma (RRMM): results … S Bal, J Berdeja, M Htut, M Kocoglu, T Gregory, LD Anderson, A Rossi, ... Hemasphere 7 (S3), e9863287, 2023 | 1 | 2023 |
